Are BRAF V600E and K-Ras Mutations Associated With Tumor Aggressiveness in Well-Differentiated Thyroid Cancer?

Unver M. , Makay Ö. , Kisim A., Emiroglu G., Aktas A., Atmaca H., ...Daha Fazla

INTERNATIONAL SURGERY, cilt.104, ss.99-106, 2019 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 104
  • Basım Tarihi: 2019
  • Doi Numarası: 10.9738/intsurg-d-14-00145.1
  • Sayfa Sayıları: ss.99-106


Aim: Many clinical studies have shown an association between B-type rapidly growing fibrosarcoma kinase [BRAF(V600E)] mutation and aggressive clinicopathologic features, although some results from others are controversial. Besides, Kirsten rat sarcoma (K-Ras) mutations are more common in endemic iodine deficiency regions, as our country is. However, use of the biologic markers are questioned in clinical practice; they are beginning to be used for the management of patients with thyroid nodules and cancers. The aim of the present study was to evaluate the prevalence of the BRAF(V600E) mutation in tumor samples and its relationship to high-risk clinicopathologic features.